Latest Organic reactions Stories
Delivering novel fluorination tools for drug and material development SAN FRANCISCO, July 31, 2014 /PRNewswire/ -- Catylix, Inc.
Researchers at ITbM, Nagoya University developed a new nickel catalyst with a "Kabuto-like" structure that was found to catalyze the cross-coupling reaction between carbonyl compounds and readily available phenol derivatives, to form alpha-arylketones, which are found in many biologically active compounds (Kabuto = a helmet worn by Japanese samurai).
Drugs that inhibit the activity of enzymes called histone deacetylases (HDACs) are being widely developed for treating cancer and other diseases, with two already on the market.
When stretched out, the genome of a single human cell can reach six feet.
Scientists at The Scripps Research Institute have discovered that DNA stays too tightly wound in certain brain cells of schizophrenic subjects.
SAN DIEGO, April 8, 2011 /PRNewswire/ -- Polaris Group (Polaris) announced today that data from preclinical studies suggest ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic, may be effective in treating acute myeloid leukemia (AML), glioblastoma multiforme (GBM) and bladder cancer.
DALLAS, February 1, 2011 /PRNewswire/ -- According to a new market research report, 'Global Refinery Catalyst Market - FCC ,HTC , HCC by units, geography, ingredients and applications (2010 - 2015)' ( http://www.marketsandmarkets.com/Market-Reports/refinery-catalyst-advanced-te chnologies-and-global-market-84.html), published by MarketsandMarkets (http://www.marketsandmarkets.com), the total global refinery catalyst market is expected to be worth US$3.4 billion by 2015 .
To understand the emerging science of epigeneticsâ€”a field that describes how genes may be regulated without altering the underlying DNA itselfâ€”scientists are deciphering the many ways in which enzymes act on the proteins surrounding DNA within cells.